Access to anti-retroviral drugs, male in Cape Verde

Cape Verde: Access to anti-retroviral drugs, male was 64.0% in 2024. ◆ Volatile

Latest (2024)
64.0%
Change on year
up 4.9%
World rank
87th
of 141 countries
All-time high
64.0%
in 2021
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Cape Verde, 2000–2024

02040602000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 10 %2006: 15 %2007: 22 %2008: 27 %2009: 26 %2010: 33 %2011: 33 %2012: 39 %2013: 46 %2014: 45 %2015: 44 %2016: 43 %2017: 44 %2018: 53 %2019: 56 %2020: 59 %2021: 64 %2022: 61 %2023: 61 %2024: 64 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in Cape Verde stood at 64.0%. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 4.9% on the previous year and up 42.2% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Cape Verde peaked at 64.0% in 2021 and was at its lowest, 0.0%, in 2000.

That places Cape Verde 87th out of 141 countries with data for 2024, putting it in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Cape Verde, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Cape Verde, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 10.0%
2006 15.0% +50.0%
2007 22.0% +46.7%
2008 27.0% +22.7%
2009 26.0% -3.7%
2010 33.0% +26.9%
2011 33.0% +0.0%
2012 39.0% +18.2%
2013 46.0% +17.9%
2014 45.0% -2.2%
2015 44.0% -2.2%
2016 43.0% -2.3%
2017 44.0% +2.3%
2018 53.0% +20.5%
2019 56.0% +5.7%
2020 59.0% +5.4%
2021 64.0% +8.5%
2022 61.0% -4.7%
2023 61.0% +0.0%
2024 64.0% +4.9%

Averages by decade

DecadeAverage LowestHighest Years
2000s 10.0% 0.0% 27.0% 10
2010s 43.6% 33.0% 56.0% 10
2020s 61.8% 59.0% 64.0% 5

Countries ranked near Cape Verde

  1. 87 Colombia 64.0% compare
  2. 87 Guinea 64.0% compare
  3. 87 Jordan 64.0% compare
  4. 87 Mali 64.0% compare

See the full ranking of 160 places →

More gender data for Cape Verde

All data for Cape Verde →

Frequently asked questions

What is access to anti-retroviral drugs, male in Cape Verde?
Access to anti-retroviral drugs, male in Cape Verde was 64.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Cape Verde?
The highest recorded value was 64.0% in 2021.
What is the lowest access to anti-retroviral drugs, male recorded in Cape Verde?
The lowest recorded value was 0.0% in 2000.
How does Cape Verde rank for access to anti-retroviral drugs, male?
Cape Verde ranks 87th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Cape Verde?
Over the last ten years it is up 42.2%. The long-run trend across the full record is volatile.
Where does this Cape Verde data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Cape Verde. Statizoid, drawing on UNAIDS estimates. Retrieved 09 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/cabo-verde/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/cabo-verde/">Access to anti-retroviral drugs, male in Cape Verde</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.